ThinkSabio

$RYTM

$107.01▲ +23.8% YTD

10 SEC 13D/G filings tracked · Last updated Nov 4, 2026

Filing History
News
RYTM ▲ +23.8% - Rhythm Pharmaceuticals, Inc.
CP $107.01▲ +23.8%Nov 4, 2026 · ThinkSabio Blog

$RYTM -- Halted -- AstraZeneca Made $124 Per Share Offer for Rhythm Pharmaceuticals Last Month, Sources Say -- WSJ (SM Circulations)…

News
RYTM ▼ -0.9% - Rhythm Pharmaceuticals, Inc.
CP $85.70▲ -0.9%Nov 4, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome…

News
RYTM ▼ -3.8% - Rhythm Pharmaceuticals, Inc.
CP $90.00▲ -3.8%Nov 3, 2026 · ThinkSabio Blog

$RYTM reported Q3 2026 EPS of -$0.61, beating the -$0.73 estimate by 16.4%. Revenue of $92.1M beat the $84.6M estimate by 8.9%…

News
RYTM ▼ -3.8% - Rhythm Pharmaceuticals, Inc.
CP $90.00▲ -3.8%Nov 3, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update…

News
RYTM ▲ +1.0% - Rhythm Pharmaceuticals, Inc.
CP $93.44▲ +1.0%Nov 3, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement…

News
RYTM ▲ +0.3% - Rhythm Pharmaceuticals, Inc.
CP $90.50▲ +0.3%Oct 21, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026…

News
RYTM ▼ -2.5% - Rhythm Pharmaceuticals, Inc.
CP $87.53▲ -2.5%Oct 13, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity…

SEC 13D/G
RYTM - Rhythm Pharmaceuticals, Inc. - SEC Filing Update (13-OCT-2026) | ThinkSabio - Stocks Simplified
$87.47▼ -16.77%Oct 13, 2026 · ThinkSabio Blog

$RYTM SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RYTM Rhythm Pharmaceuticals, Inc. : $87.47 Sector: Healthcare |…

News
RYTM ▼ -0.0% - Rhythm Pharmaceuticals, Inc.
CP $98.82▲ -0.0%Sep 22, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 y…

News
RYTM ▲ +0.4% - Rhythm Pharmaceuticals, Inc.
CP $101.49▲ +0.4%Sep 10, 2026 · ThinkSabio Blog

$RYTM - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting…